# Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

> **NCT04644120** · PHASE1 · COMPLETED · sponsor: **AbbVie** · enrollment: 25 (actual)

## Conditions studied

- CoronaVirus Disease-2019 (COVID-19)

## Interventions

- **DRUG:** ABBV-47D11
- **DRUG:** Placebo for ABBV-47D11
- **DRUG:** ABBV-2B04
- **DRUG:** Placebo for ABBV-2B04

## Key facts

- **NCT ID:** NCT04644120
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-10
- **Primary completion:** 2021-08-24
- **Final completion:** 2021-08-24
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2021-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04644120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04644120, "Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04644120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*